Sanofi licensed sotagliflozin, a dual SGLT1/SGLT2 inhibitor, from Lexicon for global development and commercialization in diabetes and cardiovascular disease. Lexicon received $300M upfront, $100M equity, with up to $2.42B in milestones. The deal was terminated by Sanofi in 2019 following regulatory setbacks. Lexicon later independently obtained approval for Inpefa (sotagliflozin) for heart failure in 2023.
Key facts
AnnouncedNov 03, 2015
ClosedNov 06, 2015
Deal value$1.7B
Deal typeLicensing/Option
Therapeutic areaCardiovascular, Metabolic
IndicationsType 1 Diabetes, Type 2 Diabetes, Heart Failure